Clinical Trial Update: Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating everolimus for adults with advanced pancreatic neuroendocrine tumors not responding to chemotherapy, assessing safety and effic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Islet Cell Carcinoma, Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-03-30